Neuropathy and Anti-GFAP Antibodies

Study of the Consequences of Anti-GFAP Antibodies on the Peripheral Nervous System

Status

UNKNOWN

Phases

Unknown

Study type

Observational

Source

ClinicalTrials.gov

Registry ID

NCT05742087

Acronym

Neuro-GFAP

Enrollment

120

Registered

2023-02-23

Start date

2022-09-01

Completion date

2023-05-01

Last updated

2023-02-23

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Neurological Diseases Associated to Anti GFAP Antibodies, Neurological Diseases or Conditions

Keywords

GFAP, neuropathy

Brief summary

Anti-Glial Fibrillary Acidic Protein (GFAP) are antibodies associated to inflammatory diseases of the central nervous system. The GFAP protein is highly expressed by astrocytes explaining these syndromes, but GFAP is also expressed by immature and non-myelinating Schwann cells. Thus, these antibodies could also lead to damages of the peripheral nervous system (PNS). Moreover, such damages have already been reported on small studies, and there is a need for larger cohorts. The investigators will use the cohort of patients with neurological syndromes and anti-GFAP antibodies identified in the cerebrospinal fluid (CSF) of the Reference center for paraneoplastic neurological syndromes and autoimmune encephalitis to determine the frequency of the PNS involvement in these patients.

Interventions

OTHERClinical examination

The examination performed by the clinician of the patient will be analyzed from the cohort as previously explained.

OTHERelectroneuromyography (ENMG)

Data from the ENMGs will be extracted from the cohort and analyzed.

Study design

Observational model

COHORT

Time perspective

RETROSPECTIVE

Eligibility

Sex/Gender

ALL

Age

18 Years to No maximum

Healthy volunteers

Inclusion criteria

* \- Age \> 18 years old * Neurological symptoms * Anti-GFAP antibodies identified in the CSF

Exclusion criteria

* \- Uncomplete data in the medical records of patients

Design outcomes

Primary

Measure	Time frame	Description
Cranial nerves abnormality at clinical examination of abnormal ENMG	Immediately after diagnosis	Data concerning the clinical examination and the ENMG will be extracted from the cohort of patients with neurological syndroms and anti-GFAP antibodies identified in the cerebrospinal fluid (CSF) of the Centre de reference des syndromes neurologiques paranéoplasiques et encéphalites auto-immunes.

Countries

France

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026